Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03403634 · ClinicalTrials.gov registry record · Phase 2

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

A Phase 2 study of Stage IV Colorectal Cancer AJCC v7 and Stage IVA Colorectal Cancer AJCC v7, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
Phase 2
Development phase
19
Enrollment target
1
Study location

NCT03403634 is a Phase 2 study of Stage IV Colorectal Cancer AJCC v7 and Stage IVA Colorectal Cancer AJCC v7 that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 19 participants, below the 84-participant average among 7 other Stage IV Colorectal Cancer AJCC v7 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03403634, a Phase 2 study of Stage IV Colorectal Cancer AJCC v7 and Stage IVA Colorectal Cancer AJCC v7, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

This early phase IIA trial studies how well celecoxib, recombinant interferon alfa-2b, and rintatolimod work in treating patients with colorectal cancer that as spread to the liver. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b is a substance that can improve the body's natural response and may interfere with the growth of tumor cells. Rintatolimod may stimulate the immune system. Giving celecoxib, recombinant interferon alfa-2b, and rintatolimod may work better at treating colorectal cancer that has spread to the liver.

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Celecoxib
  • BIOLOGICAL Recombinant Interferon Alfa-2b
  • DRUG Rintatolimod

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2018-04-19
Est. Completion 2021-08-29
Phase Phase 2

Sponsor

Roswell Park Cancer Institute

365 total trials

What the Registry Record Tells You About NCT03403634

The ClinicalTrials.gov registry entry for NCT03403634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 84-participant average among 7 other Stage IV Colorectal Cancer AJCC v7 trials with a reported enrollment target (77% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Stage IV Colorectal Cancer AJCC v7 appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT03403634 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03403634 about?

NCT03403634 is a clinical study titled "Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver". This early phase IIA trial studies how well celecoxib, recombinant interferon alfa-2b, and rintatolimod work in treating patients with colorectal cancer that as spread to the liver. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant inter...

What is the current status of trial NCT03403634?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-04-19. Estimated completion is 2021-08-29.

What conditions does trial NCT03403634 study?

This clinical trial studies the following conditions: Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Recurrent Colorectal Carcinoma, Metastatic Carcinoma in the Liver.

What interventions are being tested in trial NCT03403634?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Celecoxib (DRUG), Recombinant Interferon Alfa-2b (BIOLOGICAL), Rintatolimod (DRUG).

Who is sponsoring clinical trial NCT03403634?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03403634 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage IV Colorectal Cancer AJCC v7

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.